Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: Results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 233-237

  Van Der Heijde, D ^a   Fleischmann, R ^b   Wollenhaupt, J ^c   Deodhar, A ^d   Kielar, D ^e   Woltering, F ^e   Stach, C ^e   Hoepken, B ^e   Arledge, T ^e   Mease, P J ^f  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Schoen Klinik   (Germany)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UCB PHARMA   (Belgium)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; PLACEBO;

ARTICLE; BONE RADIOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LINEAR IMPUTATION; MAJOR CLINICAL STUDY; METHODOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; TOTAL SHARP SCORE;

ANTI-TNF; OUTCOMES RESEARCH; PSORIATIC ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLACEBOS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84889657887     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203697     Document Type: Article

References (13)

1. Van Der Heijde D. Use of imaging as an outcome measure in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in clinical trials. In: Hochberg MC, Silman AJ, Smolen JS, et al. eds. Rheumatology. 5th edn. Elsevier, 2011:413-24.
2. Kavanaugh A, McInnes I, Mease PJ, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
3. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
4. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43. (Pubitemid 44133266)
5. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17.
6. van der Heijde D, Tanaka Y, Fleischmann RM, et al. Tofacitinib, an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: year 2 efficacy and safety results from a 24-month phase 3 study. Arthritis Rheum 2012;64:546.
7. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-57. (Pubitemid 41113349)
8. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase III double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2013. 2014;73:48-55.
9. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
10. van der Heijde D, Sharp J, Wassenberg S, et al. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005;64(Suppl 2):ii61-4. (Pubitemid 40288525)
11. van der Heijde D, Simon L, Smolen J, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002;47:215-18. (Pubitemid 34303850)
12. Smolen J, Landewé RB, Mease PJ, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797.
13. Keystone E, van der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.